SHANGHAI, Oct. 14 /PRNewswire-Asia/ -- A delegation from the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (All-CABPA) visited Sundia in Shanghai's famous Zhangjiang Hi-Tech Park on October 12.
The delegation consists of 13 members from SAPA, CABS, SABPA, and CABA, the four major associations for Chinese-American professionals in biotechnology and pharmaceutical industries in the U.S. They were invited to visit Shanghai by Zhangjiang Hi-Tech Park and the Commission of Science and Technology of the Municipal Government of Shanghai. In addition to Shanghai, they will also visit Suzhou and Wuxi. The group is using this opportunity to gather up-to-date information about the development of Chinese pharmaceutical and biotech industries, as well as looking for collaborations opportunities.
In the morning of October 12, all delegates flied to Shanghai from New Jersey, Boston, San Francisco, and San Diego, U.S. During their half day visit to Sundia, Dr. Xiaochuan Wang, the Chairman and CEO of Sundia welcomed the delegation and gave them a review about the development of Chinese CRO industry and the growth of Sundia. In her presentation, she mentioned that Sundia and many other CRO companies in China are continuing to hire experienced biomedical scientists and managers at senior and middle levels from the U.S. The delegation also spent time visiting Sundia's R&D facilities and meeting Sundia's scientists to hear their stories about conducting biomedical research in China.
Mr. Lanzhong Wang, General Manager of Zhangjiang Biotech-Pharmaceutical
Base hosted the delegation in the afternoon. The Base is a part of the famous
Zhangjiang Hi-Tech Park with focus on biotech and pharmaceutical sectors. He
presented to the delegation the Base's history and current status, especially
many incentive policies and practices to attract investment for startup
high-tech companies in the park.
|SOURCE Sundia MediTech Company|
Copyright©2009 PR Newswire.
All rights reserved